Glenmark Pharmaceuticals has scheduled a Board meeting on September 26, 2025, to consider and approve the payment of an interim dividend on equity shares for the financial year 2025-26, if any. The record date for determining shareholders eligible for the dividend will be Tuesday, September 30, 2025. The company has also announced the closure of the Trading Window for designated persons until September 28, 2025.
Interim Dividend Consideration
The Board of Directors of Glenmark Pharmaceuticals is set to meet on September 26, 2025, to discuss and potentially approve an interim dividend payout. This decision will impact shareholders holding equity shares of the company.
Record Date
The record date, which determines the eligibility of shareholders for receiving the interim dividend (if declared), is fixed for Tuesday, September 30, 2025.
Trading Window Closure
In line with company policy regarding insider trading, the Trading Window for designated persons has been closed and will remain so until Sunday, September 28, 2025. This measure ensures compliance and prevents any potential misuse of information related to the dividend decision.
Source: BSE
